NULIBRY (fosdenopterin hydrobromide)
METABOLIC DISEASE ENZYME REPLACEMENT, MOCD · MOLYBDENUM COFACTOR DEFICIENCY TYPE A
SENTYNL THERAPU
Drug class
Metabolic Disease Enzyme Replacement, MoCD
"Metabolic Disease Enzyme Replacement, MoCD" is a compendial and formulary classification term rather than a standard pharmacologic class, primarily utilized by drug pricing databases to categorize substrate replacement therapy for molybdenum cofactor deficiency. Read more about Metabolic Disease Enzyme Replacement, MoCD
1 drugs in this class 1 manufacturers
Drugs in Metabolic Disease Enzyme Replacement, MoCD
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement, MoCD preselected. Add indication or manufacturer filters there.
"Metabolic Disease Enzyme Replacement, MoCD" is a compendial and formulary classification term rather than a standard pharmacologic class, primarily utilized by drug pricing databases to categorize substrate replacement therapy for molybdenum cofactor deficiency.
Rather than supplying an actual enzyme, the sole agent categorized under this heading—fosdenopterin—is an exogenous synthetic precursor that substitutes for missing cyclic pyranopterin monophosphate.
This restores downstream molybdenum cofactor biosynthesis and activates vital molybdenum-dependent enzymes such as sulfite oxidase.
Therapeutically, it is indicated specifically to reduce the risk of mortality and severe neurodegeneration in pediatric and adult patients with molybdenum cofactor deficiency Type A.
-
cigna.com
"Metabolic Disease Enzyme Replacement, MoCD" is a compendial and formulary classification term rather than a standard pharmacologic class, primarily utilized by drug pricing databases to categorize substrate replacement therapy for molybdenum cofactor deficiency
-
cigna.com
"Metabolic Disease Enzyme Replacement, MoCD" is a compendial and formulary classification term rather than a standard pharmacologic class, primarily utilized by drug pricing databases to categorize substrate replacement therapy for molybdenum cofactor deficiency
-
eurekalert.org
Rather than supplying an actual enzyme, the sole agent categorized under this heading—fosdenopterin—is an exogenous synthetic precursor that substitutes for missing cyclic pyranopterin monophosphate Therapeutically, it is indicated specifically to reduce the risk of mortality and severe neurodegeneration in pediatric and adult patients with molybdenum cofactor deficiency Type A
-
nulibry.com
This restores downstream molybdenum cofactor biosynthesis and activates vital molybdenum-dependent enzymes such as sulfite oxidase
-
ajmc.com
Therapeutically, it is indicated specifically to reduce the risk of mortality and severe neurodegeneration in pediatric and adult patients with molybdenum cofactor deficiency Type A
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.